Molecules 2017, 22, 371
9 of 11
(C-2), 79.9 (Boc
(Boc C-(
C
-(CH3)3), 58.8 (C-14), 53.5 (C-8), 52.3 (C-16), 46.9 (C-11), 38.9 (C-7), 29.0 (C-12), 28.3
C
H3)3), 24.5 (C-13), HRESIMS m/z 493.0945 [M + Na]+ (calcd. for C20H26BrN2O6Na, 493.0945).
Methyl ((S)-3-(3-bromo-4-hydroxyphenyl)-2-((tert-butoxycarbonyl)amino)propanoyl)-L-prolinate
(13b):
prepared from 11 (1.8 g, 5.0 mmol) and 12b (0.83 g, 5.0 mmol) in 50 mL of solvent (DIPEA 1.42 g,
11.0 mmol; TBTU 1.90 g, 5.9 mmol); white oil; [α]2D0 +0.39 (c 0.77, CHCl3), 1H-NMR (500 MHz, CDCl3)
mixture of rotamers
δ 7.55 and 7.37 (d, J = 2.1 Hz, 1H, H-3), 7.25 and 7.10 (dd, J = 8.3, 2.2 Hz, 1H, H-5),
7.04 and 6.89 (d, J = 8.3 Hz, 1H, H-6), 4.82 and 4.60 (q, J = 6.6 Hz, 1H, H-8), 4.40 and 4.50 (dd, J = 8.4, 4.1
Hz, 1H, H-14), 3.62 and 3.75 (s, 3H, O-CH3), 3.40, 3.21 and 3.67–3.55 (m, 2H, H-11a and H-11b), 3.35
and 3.02 (dd, J = 13.9, 6.7 Hz, 1H, H-7a), 3.17 and 2.82 (dd, J = 13.9, 5.9 Hz, 1H, H-7b), 2.18 and 2.05 (m,
1H, H-12a), 1.96 and 1.81 (m, 1H, H-12b), 2.02–1.88 and 1.74 (m, 2H, H-13a and H-13b), 1.39 (s, 9H, Boc
C-(CH3)3), 13C-NMR (125 MHz, CDCl3)
δ
172.5 and 172.2 (C-15), 170.2 and 170.1 (C-9), 155.2 (Boc
C
= O), 148.5 and 148.2 (C-1), 134.7 and 133.1 (C-3), 129.7 (C-4), 130.3 and 130.1 (C-5), 123.3 and 116.4
(C-6), 109.8 and 109.7 (C-2), 80.1 (Boc C-(CH3)3), 59.2 and 53.1 (C-14), 54.6 and 52.8 (C-8), 52.5 and 52.4
(C-16), 47.2 (C-11), 38.3 and 37.3 (C-7), 30.7 and 29.2 (C-12), 28.4 (Boc C-(CH3)3), 25.0 and 22.4 (C-13),
HRESIMS m/z 493.0941 [M + Na]+ (calcd. for C20H26BrN2O6Na, 493.0945).
3.10. Deprotection and Cyclization
Compounds 13a (0.44 g, 0.9 mmol) and 13b (0.23 g, 0.5 mmol)) were poured into a reactor with
respectively 15 mL and 3 mL of water and heated to 130 ◦C during 4 h as described in literature for
a one-pot deprotection and cyclization [20]. After cooling, the reaction mixture was extracted three
times with 15 mL of ethyl acetate. The organic layer was desiccated with Na2SO4 and dried under
vacuum. The residues were purified on silica gel using different eluent systems: 100% ethyl acetate
for compound 13a and dichloromethane/ethyl acetate (60:40) for compound 13b. These purifications
yielded to the final products 6 (64%) and 7 (36%).
3.11. Analytical Data
All fractions were analyzed with HPLC-UV using a Prevail C18 column with a gradient of H2O
(A)/acetonitrile (B): 5 min 100:0, 30 min from 0% of B to 100% of B, 10 min 100% B followed by
equilibration of the column.
Cyclo (L-Pro-L-O-Met) (
1
): 6.9 mg, white amorphous powder; rt: 18.8 min, [α]D20
−
4.0 (c 1, MeOH),
1H-NMR (CDCl3, 500 MHz) and 13C-NMR data (CDCl3, 125 MHz) as described in the literature [12],
HRESIMS m/z 245.1277 [M + H]+ (calcd. for C10H17N2O3S, 245.0955).
Cyclo (L-Pro-L-Tyr) (
1H-NMR (CD3OD, 500 MHz) and 13C-NMR data (CD3OD, 125 MHz) as described in the literature [13
HRESIMS m/z 261.1225 [M + H]+ (calcd. for C14H17N2O3, 261.1234).
2
): 5.7 mg, white amorphous powder; r.t.: 20.7 min, [α]2D0 +15.7 (c 1, MeOH),
Cyclo (D-Pro-L-Tyr) (
3
): 8.5 mg, white amorphous powder; r.t.: 21.1 min, [α]D20
−
38.2 (c 1, MeOH),
1H-NMR (CD3OD, 500 MHz) and 13C-NMR data (CD3OD, 125 MHz) as described in the literature [13],
HRESIMS m/z 261.1225 [M + H]+ (calcd. for C14H17N2O3, 261.1234).
Cyclo (L-Pro-L-Val) (
4
): 1.1 mg, white amorphous powder; r.t.: 21.9 min, [α]D20
−
23.0 (c 1, CHCl3),
1H-NMR (CD3OD, 500 MHz) and 13C-NMR data (CD3OD, 125 MHz) as described in the literature [14],
HRESIMS m/z 197.1282 [M + H]+ (calcd. for C10H17N2O2, 197.1285).
Cyclo (L-Pro-L-Leu) (
1H-NMR (CD3OD, 500 MHz) and 13C-NMR data (CD3OD, 125 MHz) as described in the literature [14
HRESIMS m/z 211.1438 [M + H]+ (calcd. for C11H19N2O2, 211.1441).
5
): 4.3 mg, white amorphous powder; r.t.: 24.1 min, [α]D20
−
27.4 (c 1, MeOH),
Cyclo (D-Pro-L-Br-Tyr) (6
): 1.4 mg, white amorphous powder; r.t.: 23.4 min, [α]2D0 +38.4 (c 0.77, MeOH),
1H-NMR (CD3OD, 500 MHz) and 13C-NMR data (CD3OD, 125 MHz) as described in Table 1, HRESIMS
m/z 339.0329 [M + H]+ (calcd. for C14H16BrN2O3, 339.0339).